CLINICAL DEVELOPMENT IN ONCOLOGY I
mmuno-oncology is revolutionizing the pharmaceutical industry by leveraging advanced technologies to enhance
treatment options. Recent patents, such as those targeting DPP4 for improved lymphocyte trafficking and using IL-7Ra agonist peptides for immune cell growth, are driving significant innovations in the field. Job postings in immuno-oncology have recently grown, and strategic deals have increased, reflecting the industry’s strong focus and investment in developing effective therapies.
Diverse applications of immuno-oncology in the pharmaceutical industry Pharma companies are leveraging new immuno-oncology technologies through recent patents to innovate and improve cancer treatment. The Pasteur Institute’s patent focuses on enhancing tumor immunity and immunotherapy by inhibiting Dipeptidylpeptidase 4 (DPP4) to improve lymphocyte trafficking. Medikine Inc’s patent involves using IL-7Ra?c agonist peptides in cell manufacturing to selectively grow immune cell populations for immunotherapy. Additionally, HuBit Genomix Inc’s patent offers a method for preventing allergic disorders in infants through IgE-class-specific immunosuppression. These patents showcase advancements in targeting cancer cells and enhancing immune responses, offering potential benefits for the acquirer in developing more effective and targeted immuno-oncology therapies. The industry experienced a 20% decline in the number of immuno-oncology-related patent applications in Q1 2024 compared with the previous quarter. On an annual basis, the number of immuno-oncology-related patent applications in the pharmaceutical industry witnessed a drop of 10% compared with Q1 2023.
Strategic deal trends in immuno-oncology in the pharmaceutical industry Pharmaceutical companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in immuno-oncology. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals
26 | Clinical Trials in Oncology
underscore the importance of immuno-oncology in the pharmaceutical industry. In Q1 2024, the number of immuno-
oncology-related deals in the pharmaceutical industry declined by 11% compared with Q1 2023. On a quarterly basis, there was 12% increase in the number of deals in Q1 2024 compared with the previous quarter.
Impact on hiring In terms of new job postings, in Q1 2024 the pharmaceutical industry experienced 24% growth compared with the previous quarter. On an annual basis, job postings declined by 7%. Notably, management occupations, with a share of 28%, emerged as the top immuno- oncology-related job roles within the pharmaceutical industry in Q1 2024, with new job postings rising by 44% quarter-on-quarter. Life, physical, and social science occupations came in second with a share of 24% in Q1 2024, with new job postings dropping by 26% over the previous quarter. The other prominent immuno- oncology roles include business and financial operations occupations with a 5% share in Q1 2024, and healthcare practitioners and technical occupations with a 4% share of new job postings. Dendreon Pharmaceuticals, MallInckrodt, ImmunityBio, AstraZeneca, and BioNTech are among the top companies leading in immuno-oncology hiring within the pharmaceutical industry.
Countries driving adoption of immuno- oncology in the pharmaceutical industry The US is the leading country in immuno- oncology adoption within the pharmaceutical industry, boasting the highest number of immuno-oncology-related patents, jobs, and deals. Meanwhile, China, Australia, Canada and South Korea also maintain significant positions in immuno-oncology adoption within the pharmaceutical industry. In conclusion, immuno-oncology is
transforming the pharmaceutical industry through innovative patents and strategic investments, thus driving advancements in treatment options. The increasing focus on this field is reflected in the trends of rising job postings and strategic deals, highlighting its growing importance and impact.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
